IPM Take
This is the hard edge of precision neurology. For Huntington’s disease, waiting for conventional placebo-controlled evidence can mean asking patients to spend years in decline while the disease moves past the window where intervention may matter most. But accepting external controls too easily risks approving a therapy without reliable proof. AMT-130 is therefore not only a gene therapy story. It is a test of whether regulators can build credible evidence pathways for irreversible, rare neurodegenerative disease.
Executive Summary
uniQure’s AMT-130, an investigational one-time gene therapy for Huntington’s disease, has become a flashpoint in regulatory evidence standards. In March 2026, uniQure stated that FDA did not agree that Phase I/II data compared with an external control were sufficient to provide primary evidence of effectiveness for a marketing application, and that FDA strongly recommended a prospective, randomised, double-blind, sham surgery-controlled study. Reuters reported the same regulatory setback and later described strong FDA criticism of the company’s external-control comparison. In April 2026, uniQure announced that it had completed a UK MHRA pre-submission meeting and expected to submit a UK marketing authorisation application in the third quarter of 2026, based on three-year Phase I/II data. The company says high-dose AMT-130 was associated with a 75 percent slowing of disease progression compared with a propensity score-matched external control.
Why it matters
- Regulators: Need to decide when external-control evidence can support access in rare, progressive and irreversible neurological disease.
- HTA bodies / payers: Will need to judge uncertainty, durability, one-time treatment value and long-term follow-up requirements if the therapy reaches assessment.
- Patients / advocates: Face the hardest trade-off: faster access under uncertainty, or stronger evidence that may take years to generate.
Before AMT-130, Huntington’s disease had no approved disease-modifying gene therapy. Development has always faced a difficult trial-design problem: the condition is rare, progressive and irreversible, while long placebo-controlled trials may be ethically and practically difficult.
What has changed is the regulatory split. In the United States, FDA has challenged whether Phase I/II data compared with an external control can support a marketing application and has recommended a new sham-controlled study. In the United Kingdom, uniQure is moving toward a marketing authorisation application after a pre-submission meeting with MHRA.
The affected population is people living with Huntington’s disease, especially those still within a stage where intervention could plausibly preserve function. The evidence question matters because delay is not neutral in a progressive neurodegenerative disease. But neither is weak evidence, especially for a one-time brain-delivered gene therapy that would be difficult to reverse once administered.
For IPM, the implication is direct: precision neurology needs evidence models that are scientifically credible, ethically defensible and fast enough for diseases where waiting can mean irreversible decline. AMT-130 should be framed as an evidence-pathway test, not as a settled access breakthrough.
